{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:08:11Z","timestamp":1792692491224,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"DOI":"10.1007\/s10787-026-02408-x","type":"journal-article","created":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:46:09Z","timestamp":1790484369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["NLRP3 Inflammasome Inhibitors as Precision Anti-inflammatory Pharmacotherapy: Translational Advances, Clinical Evidence, and Disease-specific Challenges"],"prefix":"10.1007","author":[{"given":"MD Farhan","family":"Raza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Hibah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laiba","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farheen","family":"Aftab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Devi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanchi","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3102-0069","authenticated-orcid":false,"given":"Sourabh","family":"Kosey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,27]]},"reference":[{"issue":"9","key":"2408_CR1","doi-asserted-by":"publisher","first-page":"e92361","DOI":"10.7759\/cureus.92361","volume":"17","author":"A Ahsan","year":"2025","unstructured":"Ahsan A, Sahu MA (2025) A literature review assessing whether the use of non-steroidal anti-inflammatory drugs (NSAIDs) increases the risk of cardiovascular events. Cureus 17(9):e92361. https:\/\/doi.org\/10.7759\/cureus.92361","journal-title":"Cureus"},{"issue":"7","key":"2408_CR2","doi-asserted-by":"publisher","first-page":"5223","DOI":"10.1021\/acs.jmedchem.3c00175","volume":"66","author":"V Albanese","year":"2023","unstructured":"Albanese V et al (2023) Novel aryl sulfonamide derivatives as NLRP3 inflammasome inhibitors for the potential treatment of cancer. J Med Chem 66(7):5223\u20135241. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c00175","journal-title":"J Med Chem"},{"issue":"4","key":"2408_CR3","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/brain\/awaf372","volume":"149","author":"EA Albornoz","year":"2026","unstructured":"Albornoz EA et al (2026) PET-MRI biomarkers reveal efficacy of a novel NLRP3 inhibitor in Parkinson\u2019s disease models. Brain 149(4):1289\u20131301. https:\/\/doi.org\/10.1093\/brain\/awaf372","journal-title":"Brain"},{"issue":"3","key":"2408_CR4","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.kint.2017.09.022","volume":"93","author":"H-J Anders","year":"2018","unstructured":"Anders H-J et al (2018) The macrophage phenotype and inflammasome component NLRP3 contributes to nephrocalcinosis-related chronic kidney disease independent from IL-1-mediated tissue injury. Kidney Int 93(3):656\u2013669. https:\/\/doi.org\/10.1016\/j.kint.2017.09.022","journal-title":"Kidney Int"},{"key":"2408_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1731165","author":"F Bai","year":"2025","unstructured":"Bai F, Wang D, Wu Y (2025) Dapansutrile in multidisciplinary therapeutic applications: mechanisms and clinical perspectives. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2025.1731165","journal-title":"Front Pharmacol"},{"issue":"3","key":"2408_CR6","doi-asserted-by":"publisher","first-page":"25970","DOI":"10.31083\/FBL25970","volume":"30","author":"S Beesetti","year":"2025","unstructured":"Beesetti S (2025) Ubiquitin ligases in control: regulating NLRP3 inflammasome activation. Front Biosci (Landmark Ed 30(3):25970. https:\/\/doi.org\/10.31083\/FBL25970","journal-title":"Front Biosci (Landmark Ed"},{"key":"2408_CR7","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3389\/fmed.2018.00316","volume":"5","author":"JM Bennett","year":"2018","unstructured":"Bennett JM, Reeves G, Billman GE, Sturmberg JP (2018) Inflammation\u2013nature\u2019s way to efficiently respond to all types of challenges: implications for understanding and managing \u2018the epidemic\u2019 of chronic diseases. Front Med 5:316. https:\/\/doi.org\/10.3389\/fmed.2018.00316","journal-title":"Front Med"},{"key":"2408_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.879021","author":"HM Blevins","year":"2022","unstructured":"Blevins HM, Xu Y, Biby S, Zhang S (2022) The NLRP3 inflammasome pathway: a review of mechanisms and inhibitors for the treatment of inflammatory diseases. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2022.879021","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"2408_CR9","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1186\/s12967-025-07377-3","volume":"23","author":"C Boncompagni","year":"2025","unstructured":"Boncompagni C et al (2025) Radiation meets inflammation: NLRP3 inflammasome at the core of radiation-induced cardiac injury. J Transl Med 23(1):1330. https:\/\/doi.org\/10.1186\/s12967-025-07377-3","journal-title":"J Transl Med"},{"key":"2408_CR10","doi-asserted-by":"publisher","first-page":"1761121","DOI":"10.3389\/fimmu.2026.1761121","volume":"17","author":"D Cao","year":"2026","unstructured":"Cao D, Pu H, Yuan X, Li Z, Yu X, Shi X (2026) The interplay between NLRP3 inflammasome and metabolic signals in gouty arthritis. Front Immunol 17:1761121. https:\/\/doi.org\/10.3389\/fimmu.2026.1761121","journal-title":"Front Immunol"},{"key":"2408_CR11","doi-asserted-by":"publisher","first-page":"1430236","DOI":"10.3389\/fphar.2024.1430236","volume":"15","author":"P Chen","year":"2024","unstructured":"Chen P, Li X (2024) NLRP3 inflammasome in atherosclerosis: mechanisms and targeted therapies. Front Pharmacol 15:1430236. https:\/\/doi.org\/10.3389\/fphar.2024.1430236","journal-title":"Front Pharmacol"},{"issue":"10","key":"2408_CR12","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1002\/mds.30307","volume":"40","author":"N Clarke","year":"2025","unstructured":"Clarke N et al (2025) Anti-neuroinflammatory and anti-inflammatory effects of the NLRP3 inhibitor NT-0796 in subjects with Parkinson\u2019s disease. Mov Disord 40(10):2199\u20132208. https:\/\/doi.org\/10.1002\/mds.30307","journal-title":"Mov Disord"},{"key":"2408_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1190219","author":"M-L Cl\u00e9net","year":"2023","unstructured":"Cl\u00e9net M-L et al (2023) Divergent functional outcomes of NLRP3 blockade downstream of multi-inflammasome activation: therapeutic implications for ALS. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1190219","journal-title":"Front Immunol"},{"issue":"3","key":"2408_CR14","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1124\/pharmrev.120.000171","volume":"73","author":"SE Corcoran","year":"2021","unstructured":"Corcoran SE, Halai R, Cooper MA (2021) Pharmacological inhibition of the Nod-Like receptor family pyrin domain containing 3 inflammasome with MCC950. Pharmacol Rev 73(3):968\u20131000. https:\/\/doi.org\/10.1124\/pharmrev.120.000171","journal-title":"Pharmacol Rev"},{"issue":"7293","key":"2408_CR15","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/nature08938","volume":"464","author":"P Duewell","year":"2010","unstructured":"Duewell P et al (2010) NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464(7293):1357\u20131361. https:\/\/doi.org\/10.1038\/nature08938","journal-title":"Nature"},{"key":"2408_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25235533","author":"LY El-Sharkawy","year":"2020","unstructured":"El-Sharkawy LY, Brough D, Freeman S (2020) Inhibiting the NLRP3 inflammasome. Molecules. https:\/\/doi.org\/10.3390\/molecules25235533","journal-title":"Molecules"},{"issue":"9","key":"2408_CR17","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s41569-018-0064-2","volume":"15","author":"L Ferrucci","year":"2018","unstructured":"Ferrucci L, Fabbri E (2018) Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol 15(9):505\u2013522. https:\/\/doi.org\/10.1038\/s41569-018-0064-2","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"2408_CR18","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","volume":"39","author":"C Garlanda","year":"2013","unstructured":"Garlanda C, Dinarello CA, Mantovani A (2013) The interleukin-1 family: back to the future. Immunity 39(6):1003\u20131018. https:\/\/doi.org\/10.1016\/j.immuni.2013.11.010","journal-title":"Immunity"},{"issue":"5","key":"2408_CR19","doi-asserted-by":"publisher","first-page":"e13789","DOI":"10.1111\/cts.13789","volume":"17","author":"E Gatlik","year":"2024","unstructured":"Gatlik E et al (2024) First-in-human safety, tolerability, and pharmacokinetic results of DFV890, an oral low-molecular-weight NLRP3 inhibitor. Clin Transl Sci 17(5):e13789. https:\/\/doi.org\/10.1111\/cts.13789","journal-title":"Clin Transl Sci"},{"key":"2408_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12986-015-0044-z","volume":"12","author":"S Granata","year":"2015","unstructured":"Granata S, Dalla Gassa A, Tomei P, Lupo A, Zaza G (2015) Mitochondria: a new therapeutic target in chronic kidney disease. Nutr Metab (Lond) 12:49. https:\/\/doi.org\/10.1186\/s12986-015-0044-z","journal-title":"Nutr Metab (Lond)"},{"issue":"2","key":"2408_CR21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/cei.13167","volume":"194","author":"C Guo","year":"2018","unstructured":"Guo C et al (2018) NLRP3 inflammasome activation contributes to the pathogenesis of rheumatoid arthritis. Clin Exp Immunol 194(2):231\u2013243. https:\/\/doi.org\/10.1111\/cei.13167","journal-title":"Clin Exp Immunol"},{"key":"2408_CR22","doi-asserted-by":"publisher","first-page":"816839","DOI":"10.3389\/fimmu.2021.816839","volume":"12","author":"Q Jiang","year":"2021","unstructured":"Jiang Q et al (2021) Inflammasome and its therapeutic targeting in rheumatoid arthritis. Front Immunol 12:816839. https:\/\/doi.org\/10.3389\/fimmu.2021.816839","journal-title":"Front Immunol"},{"issue":"1","key":"2408_CR23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/imr.12906","volume":"297","author":"C Kay","year":"2020","unstructured":"Kay C, Wang R, Kirkby M, Man SM (2020) Molecular mechanisms activating the NAIP\u2010NLRC4 inflammasome: implications in infectious disease, autoinflammation, and cancer. Immunol Rev 297(1):67\u201382. https:\/\/doi.org\/10.1111\/imr.12906","journal-title":"Immunol Rev"},{"issue":"11","key":"2408_CR24","doi-asserted-by":"publisher","first-page":"e1471","DOI":"10.1002\/ctm2.1471","volume":"13","author":"B Klughammer","year":"2023","unstructured":"Klughammer B et al (2023) A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis. Clin Transl Med 13(11):e1471. https:\/\/doi.org\/10.1002\/ctm2.1471","journal-title":"Clin Transl Med"},{"issue":"11","key":"2408_CR25","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1002\/art.40208","volume":"69","author":"JB Kuemmerle-Deschner","year":"2017","unstructured":"Kuemmerle-Deschner JB et al (2017) Clinical and molecular phenotypes of low-penetrance variants of NLRP3: diagnostic and therapeutic challenges. Arthritis Rheumatol (Hoboken N.J.) 69(11):2233\u20132240","journal-title":"Arthritis Rheumatol (Hoboken N.J.)"},{"key":"2408_CR26","doi-asserted-by":"publisher","first-page":"719807","DOI":"10.3389\/fimmu.2021.719807","volume":"12","author":"Y Li","year":"2021","unstructured":"Li Y et al (2021) Targeting microglial \u03b1-synuclein\/TLRs\/NF-kappaB\/NLRP3 inflammasome axis in Parkinson\u2019s disease. Front Immunol 12:719807. https:\/\/doi.org\/10.3389\/fimmu.2021.719807","journal-title":"Front Immunol"},{"key":"2408_CR27","doi-asserted-by":"publisher","first-page":"175091","DOI":"10.1016\/j.ejphar.2022.175091","volume":"928","author":"H Li","year":"2022","unstructured":"Li H et al (2022) Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome. Eur J Pharmacol 928:175091. https:\/\/doi.org\/10.1016\/j.ejphar.2022.175091","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"2408_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12964-020-00688-6","volume":"19","author":"Z Liang","year":"2021","unstructured":"Liang Z, Damianou A, Di Daniel E, Kessler BM (2021) Inflammasome activation controlled by the interplay between post-translational modifications: emerging drug target opportunities. Cell Commun Signal 19(1):23. https:\/\/doi.org\/10.1186\/s12964-020-00688-6","journal-title":"Cell Commun Signal"},{"issue":"3","key":"2408_CR29","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1124\/pharmrev.122.000629","volume":"75","author":"Q Ma","year":"2023","unstructured":"Ma Q (2023) Pharmacological inhibition of the NLRP3 inflammasome: structure, molecular activation, and inhibitor-NLRP3 interaction. Pharmacol Rev 75(3):487\u2013520. https:\/\/doi.org\/10.1124\/pharmrev.122.000629","journal-title":"Pharmacol Rev"},{"key":"2408_CR30","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.coph.2020.09.004","volume":"55","author":"A Mitrofanova","year":"2020","unstructured":"Mitrofanova A, Fontanella AM, Merscher S, Fornoni A (2020) Lipid deposition and metaflammation in diabetic kidney disease. Curr Opin Pharmacol 55:60\u201372. https:\/\/doi.org\/10.1016\/j.coph.2020.09.004","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"2408_CR31","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.kint.2019.01.014","volume":"96","author":"SR Mulay","year":"2019","unstructured":"Mulay SR (2019) Multifactorial functions of the inflammasome component NLRP3 in pathogenesis of chronic kidney diseases. Kidney Int 96(1):58\u201366. https:\/\/doi.org\/10.1016\/j.kint.2019.01.014","journal-title":"Kidney Int"},{"issue":"2","key":"2408_CR32","doi-asserted-by":"publisher","first-page":"e1000661","DOI":"10.1371\/journal.ppat.1000661","volume":"6","author":"MG Netea","year":"2010","unstructured":"Netea MG, Simon A, van de Veerdonk F, Kullberg B-J, Van der Meer JWM, Joosten LAB (2010) IL-1beta processing in host defense: beyond the inflammasomes. PLoS Pathog 6(2):e1000661. https:\/\/doi.org\/10.1371\/journal.ppat.1000661","journal-title":"PLoS Pathog"},{"issue":"6","key":"2408_CR33","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1084\/jem.20160462","volume":"214","author":"V Neudecker","year":"2017","unstructured":"Neudecker V et al (2017) Myeloid-derived miR-223 regulates intestinal inflammation via repression of the NLRP3 inflammasome. J Exp Med 214(6):1737\u20131752. https:\/\/doi.org\/10.1084\/jem.20160462","journal-title":"J Exp Med"},{"key":"2408_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17101241","author":"TU Nguyen","year":"2025","unstructured":"Nguyen TU et al (2025) LMT2368 (1-(4-chlorophenyl)-3-(3-fluoro-5-(trifluoromethyl)phenyl)urea) negatively regulates inflammation by inhibiting NLRP3 inflammasome activation. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics17101241","journal-title":"Pharmaceutics"},{"issue":"6","key":"2408_CR35","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41423-025-01284-9","volume":"22","author":"S Paik","year":"2025","unstructured":"Paik S, Kim JK, Shin HJ, Park E-J, Kim IS, Jo E-K (2025) Updated insights into the molecular networks for NLRP3 inflammasome activation. Cell Mol Immunol 22(6):563\u2013596. https:\/\/doi.org\/10.1038\/s41423-025-01284-9","journal-title":"Cell Mol Immunol"},{"key":"2408_CR36","doi-asserted-by":"publisher","first-page":"1761693","DOI":"10.3389\/fimmu.2026.1761693","volume":"17","author":"Y Qie","year":"2026","unstructured":"Qie Y, Li J, Xu Y, Liu S, Liu N, Liu Q (2026) Targeting pyroptosis in periodontitis: mechanisms and therapeutic strategies. Front Immunol 17:1761693. https:\/\/doi.org\/10.3389\/fimmu.2026.1761693","journal-title":"Front Immunol"},{"key":"2408_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1146\/annurev-nutr-071816-064836","volume":"37","author":"JC Ralston","year":"2017","unstructured":"Ralston JC, Lyons CL, Kennedy EB, Kirwan AM, Roche HM (2017) Fatty acids and NLRP3 inflammasome-mediated inflammation in metabolic tissues. Annu Rev Nutr 37:77\u2013102. https:\/\/doi.org\/10.1146\/annurev-nutr-071816-064836","journal-title":"Annu Rev Nutr"},{"key":"2408_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2026.05.014","author":"KK Ray","year":"2026","unstructured":"Ray KK et al (2026) Anti-inflammatory effects of oral NLRP3 inhibition with ruvonoflast among individuals at elevated cardiovascular risk. J Am Coll Cardiol. https:\/\/doi.org\/10.1016\/j.jacc.2026.05.014","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"2408_CR39","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1007\/s00018-012-0962-0","volume":"69","author":"A Salminen","year":"2012","unstructured":"Salminen A, Ojala J, Kaarniranta K, Kauppinen A (2012) Mitochondrial dysfunction and oxidative stress activate inflammasomes: impact on the aging process and age-related diseases. Cell Mol Life Sci 69(18):2999\u20133013. https:\/\/doi.org\/10.1007\/s00018-012-0962-0","journal-title":"Cell Mol Life Sci"},{"key":"2408_CR40","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.3389\/fimmu.2019.02578","volume":"10","author":"A S\u00e1nchez-Fern\u00e1ndez","year":"2019","unstructured":"S\u00e1nchez-Fern\u00e1ndez A, Skouras DB, Dinarello CA, L\u00f3pez-Vales R (2019) OLT1177 (Dapansutrile), a selective NLRP3 inflammasome inhibitor, ameliorates experimental autoimmune encephalomyelitis pathogenesis. Front Immunol 10:2578. https:\/\/doi.org\/10.3389\/fimmu.2019.02578","journal-title":"Front Immunol"},{"issue":"5","key":"2408_CR41","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1007\/s10787-024-01556-2","volume":"32","author":"A Satheesan","year":"2024","unstructured":"Satheesan A, Kumar J, Leela KV, Murugesan R, Chaithanya V, Angelin M (2024) Review on the role of nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome pathway in diabetes: mechanistic insights and therapeutic implications. Inflammopharmacology 32(5):2753\u20132779. https:\/\/doi.org\/10.1007\/s10787-024-01556-2","journal-title":"Inflammopharmacology"},{"issue":"1","key":"2408_CR42","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-025-01763-6","volume":"18","author":"W Seo","year":"2025","unstructured":"Seo W et al (2025) Inflammasomes and pyroptosis in cancer: mechanisms and therapeutic advances. J Hematol Oncol 18(1):113. https:\/\/doi.org\/10.1186\/s13045-025-01763-6","journal-title":"J Hematol Oncol"},{"issue":"8","key":"2408_CR43","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/ni.2639","volume":"14","author":"FJ Sheedy","year":"2013","unstructured":"Sheedy FJ et al (2013) CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat Immunol 14(8):812\u2013820. https:\/\/doi.org\/10.1038\/ni.2639","journal-title":"Nat Immunol"},{"key":"2408_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24098162","author":"DM Tanase","year":"2023","unstructured":"Tanase DM et al (2023) Portrayal of NLRP3 inflammasome in atherosclerosis: current knowledge and therapeutic targets. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24098162","journal-title":"Int J Mol Sci"},{"key":"2408_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1422249","author":"IW Tengesdal","year":"2024","unstructured":"Tengesdal IW, Banks M, Dinarello CA, Marchetti C (2024) Screening NLRP3 drug candidates in clinical development: lessons from existing and emerging technologies. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2024.1422249","journal-title":"Front Immunol"},{"key":"2408_CR46","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2147\/ITT.S288547","volume":"10","author":"S Unterberger","year":"2021","unstructured":"Unterberger S, Davies KA, Rambhatla SB, Sacre S (2021) Contribution of toll-like receptors and the NLRP3 inflammasome in rheumatoid arthritis pathophysiology. ImmunoTargets Ther 10:285\u2013298. https:\/\/doi.org\/10.2147\/ITT.S288547","journal-title":"ImmunoTargets Ther"},{"issue":"1","key":"2408_CR47","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41573-023-00822-2","volume":"23","author":"L Vande Walle","year":"2024","unstructured":"Vande Walle L, Lamkanfi M (2024) Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets. Nat Rev Drug Discov 23(1):43\u201366. https:\/\/doi.org\/10.1038\/s41573-023-00822-2","journal-title":"Nat Rev Drug Discov"},{"key":"2408_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1844319","author":"X Wang","year":"2026","unstructured":"Wang X, Chen G, Liu F (2026) Direct and indirect evidence for pyroptosis and immune dysregulation in IVF\/ICSI-ET-related early pregnancy loss. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2026.1844319","journal-title":"Front Immunol"},{"issue":"12","key":"2408_CR49","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1080\/14740338.2018.1546841","volume":"17","author":"JW Wastesson","year":"2018","unstructured":"Wastesson JW, Morin L, Tan ECK, Johnell K (2018) An update on the clinical consequences of polypharmacy in older adults: a narrative review. Expert Opin Drug Saf 17(12):1185\u20131196. https:\/\/doi.org\/10.1080\/14740338.2018.1546841","journal-title":"Expert Opin Drug Saf"},{"key":"2408_CR50","doi-asserted-by":"publisher","first-page":"634607","DOI":"10.3389\/fcell.2021.634607","volume":"9","author":"S Wei","year":"2021","unstructured":"Wei S, Ma W, Zhang B, Li W (2021) NLRP3 inflammasome: a promising therapeutic target for drug-induced toxicity. Front Cell Dev Biol 9:634607. https:\/\/doi.org\/10.3389\/fcell.2021.634607","journal-title":"Front Cell Dev Biol"},{"issue":"10","key":"2408_CR51","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1042\/BCJ20210711","volume":"479","author":"A Weir","year":"2022","unstructured":"Weir A, Vince JE (2022) No longer married to inflammasome signaling: the diverse interacting pathways leading to pyroptotic cell death. Biochem J 479(10):1083\u20131102. https:\/\/doi.org\/10.1042\/BCJ20210711","journal-title":"Biochem J"},{"key":"2408_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10010128","author":"T Welzel","year":"2021","unstructured":"Welzel T, Kuemmerle-Deschner JB (2021) Diagnosis and management of the cryopyrin-associated periodic syndromes (CAPS): what do we know today? J Clin Med. https:\/\/doi.org\/10.3390\/jcm10010128","journal-title":"J Clin Med"},{"issue":"1","key":"2408_CR53","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1007\/s11033-025-11116-8","volume":"52","author":"S Xiao","year":"2025","unstructured":"Xiao S et al (2025) The NLRP3 inflammasome: a pivotal orchestrator of multisystem diseases\u2014from molecular mechanisms to therapeutic innovation. Mol Biol Rep 52(1):1026. https:\/\/doi.org\/10.1007\/s11033-025-11116-8","journal-title":"Mol Biol Rep"},{"key":"2408_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/ph19071104","author":"Y Xu","year":"2026","unstructured":"Xu Y, Murphy S (2026) Deconstructing the master switch: advances in direct NLRP3 inhibition. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph19071104","journal-title":"Pharmaceuticals (Basel)"},{"key":"2408_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02538","author":"A Zahid","year":"2019","unstructured":"Zahid A, Li B, Kombe AJK, Jin T, Tao J (2019) Pharmacological inhibitors of the NLRP3 inflammasome. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2019.02538","journal-title":"Front Immunol"},{"key":"2408_CR56","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2023.5238","author":"X Zhang","year":"2023","unstructured":"Zhang X et al (2023) Inhibitors of the NLRP3 inflammasome pathway as promising therapeutic candidates for inflammatory diseases (Review). Int J Mol Med. https:\/\/doi.org\/10.3892\/ijmm.2023.5238","journal-title":"Int J Mol Med"},{"issue":"1","key":"2408_CR57","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41421-020-0167-x","volume":"6","author":"D Zheng","year":"2020","unstructured":"Zheng D, Liwinski T, Elinav E (2020) Inflammasome activation and regulation: toward a better understanding of complex mechanisms. Cell Discov 6(1):36. https:\/\/doi.org\/10.1038\/s41421-020-0167-x","journal-title":"Cell Discov"},{"issue":"5","key":"2408_CR58","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/s41401-021-00749-7","volume":"43","author":"C-S Zhong","year":"2022","unstructured":"Zhong C-S et al (2022) Gout-associated monosodium urate crystal-induced necrosis is independent of NLRP3 activity but can be suppressed by combined inhibitors for multiple signaling pathways. Acta Pharmacol Sin 43(5):1324\u20131336. https:\/\/doi.org\/10.1038\/s41401-021-00749-7","journal-title":"Acta Pharmacol Sin"},{"key":"2408_CR59","doi-asserted-by":"publisher","first-page":"116706","DOI":"10.1016\/j.biopha.2024.116706","volume":"175","author":"Z Zhou","year":"2024","unstructured":"Zhou Z et al (2024) Sulforaphane decreases oxidative stress and inhibits NLRP3 inflammasome activation in a mouse model of ulcerative colitis. Biomed Pharmacother 175:116706. https:\/\/doi.org\/10.1016\/j.biopha.2024.116706","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"2408_CR60","doi-asserted-by":"publisher","first-page":"e70660","DOI":"10.1002\/mco2.70660","volume":"7","author":"C Zou","year":"2026","unstructured":"Zou C, Jiang S, Li H, Zhao K, Cao D, Yang G (2026) The NLRP3 inflammasome: mechanisms of activation, regulation, and therapeutic opportunities. MedComm 7(3):e70660. https:\/\/doi.org\/10.1002\/mco2.70660","journal-title":"MedComm"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02408-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-026-02408-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02408-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T08:17:59Z","timestamp":1790583479000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-026-02408-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,27]]},"references-count":60,"alternative-id":["2408"],"URL":"https:\/\/doi.org\/10.1007\/s10787-026-02408-x","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,27]]},"assertion":[{"value":"22 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}